Fostering Collaboration to Advance Representative Enrollment in Clinical Trials

Virtual Public Convening
March 28, 2023
10:00 AM - 2:45 PM Eastern

Agenda

Meeting Objective: Building on the July 2023 Duke-Margolis public meeting, Advancing Representative Enrollment in Clinical Trials, this public convening seeks to highlight cross-cutting goals across interdisciplinary stakeholder groups to achieve representativeness in clinical trials. Topics will include building a sustainable foundation of community engagement; building and scaling innovative trial infrastructure; and funding and metrics needed to incentivize success.

10:00 a.m. Welcome and Opening Remarks
10:10 a.m. Introductory Framing Presentation
10:25 a.m. Moving Beyond Targeted Outreach Towards Continual Community Engagement
Objective: During this session, panelists will discuss collective efforts required to build a foundation of meaningful community engagement both during and after clinical trials. Panelists will address how community engagement extends beyond training and recruitment, emphasizing its wholistic and lasting impact on the community. The discussion will focus on scalable standards and the metrics needed to measure success.

Panelist Remarks
Panel Discussion & Interactive Audience Questions

11:25 a.m. Break

11:35 a.m. Building and Scaling Innovative Clinical Trial Infrastructure
Objective: During this session, panelists will discuss how leveraging innovative approaches to clinical trials can enhance representativeness and what supportive infrastructure might be required. Among other topics, panelists will address how point-of-care trials and other innovative trial approaches contribute to this effort, as well as barriers hindering progress in this area.

Panelist Remarks
Panel Discussion & Interactive Audience Questions

12:35 p.m. Break
12:50 p.m. **Funding Considerations to Increase Representativeness in Clinical Trials**  
*Objective:* This session will explore actionable pathways funders can use to improve representativeness in clinical trials through the strategic use of funding and investments. Topics discussed will include funding mechanisms, incentive structures, and the development of compelling business cases for increasing representativeness. The discussion will also expand on topics covered in previous sessions to pinpoint avenues where funding can serve as a catalyst for change.

Panelist Remarks

Panel Discussion & Interactive Audience Questions

1:50 p.m. **Future Reflections**  
*Objective:* In this closing session, panelists will reflect on the discussions throughout the day, considering how to turn collaborative priorities into action, as well as discuss potential metrics of success for such initiatives.

Panelist Remarks

Panel Discussion

2:35 p.m. **Closing Remarks**

2:45 p.m. **Adjournment**

---

*Support for this event was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.*